More recently developed FLT3 inhibitors, such as gilteritinib, have shown improved in vivo potency, significant single-agent clinical activity in FLT3mut+ R/R AML, and favorable tolerability at clinically active doses [11,12]. Here, FLT3 is linked to acute myeloid leukemia.